Clinical Effect of Revascularization Strategies and Pharmacologic Treatment on Long-Term Results in Patients with Advanced Peripheral Artery Disease with TASC C and D Femoropopliteal Lesions

Table 5

Multivariate Cox regression analysis of primary patency in the two groups.

Variable	Multivariate (EVT group)		Multivariate (bypass group)
	HR (95% CI^†)	value	HR (95% CI^†)	value
hsCRP (mg/L)	1.02 (0.54–1.92)	0.96	1.96 (0.77–5.0)	0.157
Neuropathy	0.83 (0.38–1.82)	0.648	0.89 (0.29–2.71)	0.832
Statin treatment (yes/no)	0.74 (0.38–1.45)	0.381	0.59 (0.25–1.42)	0.241
Cilostazol treatment (>3 Ms/≤3 Ms)	0.46 (0.26–0.82)	0.009	0.33 (0.15–0.75)	0.008
Insulin alone (yes/no)	0.98 (0.46–2.09)	0.966	2.72 (0.94–7.87)	0.065
DR/IR	0.43 (0.22–0.81)	0.009	0.5 (0.2–1.23)	0.132

HR, hazard ratio; ^†CI, confidence interval; DR, direct revascularization; EVT, endovascular therapy; hsCRP: high-sensitivity C-reactive protein; HA1c: hemoglobin A1c; IR, indirect revascularization.